Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp. announced its CEO will present at the 3rd Annual Leigh Syndrome Symposium, discussing TTI-0102, a potential treatment for Leigh syndrome and MELAS. The compound aims to combat mitochondrial oxidative stress by increasing glutathione levels, with Phase 2 clinical trials anticipated soon.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money